Arta M. Monjazeb

Radiology | Radiation Oncology

Mercy Cancer Center
3850 G St
Merced, CA 95340

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Journal: Oncoimmunology

Published: September 02, 2026

Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma.

Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma.

Journal: Journal for immunotherapy of cancer

Published: July 08, 2026

Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling.

Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling.

Journal: Journal for immunotherapy of cancer

Published: June 30, 2026

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Journal: Lancet (London, England)

Published: June 27, 2026

Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model.

Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model.

Journal: Blood advances

Published: January 05, 2026

Age-driven shifts in T and NK cell responses amplify inflammation and coagulopathy during viral infection in mice and humans.

Age-driven shifts in T and NK cell responses amplify inflammation and coagulopathy during viral infection in mice and humans.

Journal: Frontiers in immunology

Published: September 25, 2025

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

Journal: Oncoimmunology

Published: May 22, 2025

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.

Journal: JTO clinical and research reports

Published: October 21, 2024

Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.

Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.

Journal: The Lancet. Oncology

Published: August 07, 2024

Visceral fat area and subcutaneous fat area as measures of body composition in soft tissue sarcoma.

Visceral fat area and subcutaneous fat area as measures of body composition in soft tissue sarcoma.

Journal: Journal of surgical oncology

Published: May 31, 2024

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients.

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients.

Journal: Frontiers in immunology

Published: May 08, 2024

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.

Journal: JTO clinical and research reports

Published: May 08, 2024

Showing 1-12 of 111

Last Updated: 09/26/2026